Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:BXLT

(BXLT) (BXLT) Stock Price, News & Analysis

(BXLT) logo

About (BXLT) Stock (NYSE:BXLT)

Advanced Chart

Key Stats

Today's Range
$46.02
$46.02
50-Day Range
N/A
52-Week Range
$29.83
$46.52
Volume
N/A
Average Volume
12.66 million shs
Market Capitalization
N/A
P/E Ratio
15.49
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Receive BXLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (BXLT) and its competitors with MarketBeat's FREE daily newsletter.

BXLT Stock News Headlines

AnyMind Group Inc 5027
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
IDICO Corp JSC Ordinary Shares IDC
Hana Financial Group Inc 086790
See More Headlines

BXLT Stock Analysis - Frequently Asked Questions

(BXLT) (NYSE:BXLT) released its earnings results on Thursday, April, 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.01. The business's revenue for the quarter was up 10.3% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that (BXLT) investors own include Baxter International (BAX), Hawkins (HWKN), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), Bank of America (BAC) and Vertex Pharmaceuticals (VRTX).

Company Calendar

Last Earnings
4/28/2016
Today
5/20/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NYSE:BXLT
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
15.49
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NYSE:BXLT) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners